Safety of the PDE4 inhibitor roflumilast in COPD patients with chronic bronchitis

被引：0
|
作者：
Becker, J. C.
Pettenkofer, J.
Schmid-Wirlitsch, C. [1 ]
Gooss, A. [2 ]
机构：
[1] Nycomed Deutschland GmbH, Constance, DE, Germany
[2] Nycomed Pharma AG, Dubendorf, Switzerland
来源：
SWISS MEDICAL WEEKLY | 2010年 / 140卷 / 13-14期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：13S / 13S
页数：1
相关论文
共 50 条
  • [41] Combined Effects of the Phosphodiesterase Type 4 (PDE4) Inhibitor, Roflumilast, and the PDE5 Inhibitor, Tadalafil, in Allergen-Induced Airway Hyperresponsiveness (AHR).
    Takeda, K.
    Shiraishi, Y.
    Domenico, J.
    Loader, J. E.
    Sanjar, S.
    Lucas, J. J.
    Gelfand, E. W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [42] Systematizing PDE4 Inhibition in Psoriasis Treatment: Roflumilast Leads the Way
    Ravindran, Remya
    Muralidharan, Palayyan
    Govindarajan, Arulkumaran
    JOURNAL OF YOUNG PHARMACISTS, 2025, 17 (01) : 13 - 18
  • [43] Efficacy and Safety of CHF6001, A Novel Inhaled PDE4 Inhibitor in COPD: The Pioneer Dose Finding Study
    Singh, D.
    Nandeuil, M. A.
    Pigeon-Francisco, C.
    Emirova, A.
    Santoro, D.
    Biondaro, S.
    Cohuet, G.
    Govoni, M.
    Petruzzelli, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [44] New options in a newly assessed COPD: PDE4 inhibitor treats obstruction and inflammation
    不详
    ALLERGOLOGIE, 2006, 29 (06) : 258 - 259
  • [45] Tetomilast -: Treatment of inflammatory bowel disease treatment of COPD antioxidant PDE4 inhibitor
    McIntyre, JA
    Castañer, J
    Castañer, RM
    DRUGS OF THE FUTURE, 2004, 29 (10) : 1003 - 1006
  • [46] Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD
    Dave Singh
    Kai Michael Beeh
    Brendan Colgan
    Oliver Kornmann
    Brian Leaker
    Henrik Watz
    Germano Lucci
    Silvia Geraci
    Aida Emirova
    Mirco Govoni
    Marie Anna Nandeuil
    Respiratory Research, 20
  • [47] Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD
    Singh, Dave
    Beeh, Kai Michael
    Colgan, Brendan
    Kornmann, Oliver
    Leaker, Brian
    Watz, Henrik
    Lucci, Germano
    Geraci, Silvia
    Emirova, Aida
    Govoni, Mirco
    Nandeuil, Marie Anna
    RESPIRATORY RESEARCH, 2019, 20 (01)
  • [48] The PDE4 Inhibitor Roflumilast Reduces Weight Gain by Increasing Energy Expenditure and Leads to Improved Glucose Metabolism
    Moellmann, Julia
    Kahles, Florian
    Lebherz, Corinna
    Kappel, Ben
    Baeck, Christer
    Tacke, Frank
    Werner, Christian
    Federici, Massimo
    Marx, Nickolaus
    Lehrke, Michael
    DIABETES, 2017, 66 : A8 - A8
  • [49] Effect of Roflumilast, a non-selective PDE4 inhibitor, on Bone Phenotypes in ADO2 Mice
    Alam, Imranul
    Hardman, Sara
    Gerard-O'Riley, Rita
    Acton, Dena
    Hong, Jung
    Bruzzaniti, Angela
    Econs, Michael
    JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 290 - 291
  • [50] Ariflo™ (SB 207499), a second generation, oral PDE4 inhibitor, improves quality of life in patients with COPD
    Compton, CH
    Gubb, J
    Cedar, E
    Bakst, A
    Nieman, RB
    Amit, O
    Ayres, J
    Brambilla, C
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A522 - A522
12345